CYDY & The Adelson Medical Research Foundation?
Some context:
"Can Blocking CCR5 Improve Brain Injury and Dementia Recovery?"
For those who haven't seen it, down below is a YouTube link to a very interesting CCR5-related interview with UCLA's Dr. Carmichael, who now collaborates with CYDY...
But first, it's worth noting that the "CCR5 inhibitor" used in Dr. Carmichael's prior studies is the generic drug Maraviroc, which has black box safety warnings (aka the highest level of warning the FDA can issue for a medication's dangerous side effects) for life-threatening liver toxicity. Maraviroc appears to be inferior to CYDY's Leronlimab in both safety and efficacy (Leronlimab has an impeccable safety profile with zero reports of serious adverse events). Importantly, Leronlimab also appears to do a superior job of crossing the blood-brain barrier.
It's worth reiterating that Dr. Carmichael is now collaborating with CytoDyn regarding Leronlimab.
Here's a very interesting tidbit that I found on him...
Dr. Carmichael also works closely with the "Adelson Medical Research Foundation".
Per Google, the net worth of the Adelson family is estimated to be around $40.4 billion.
Here's some additional info on the foundation and Dr. Carmichael's affiliation with it:
https://www.adelsonfoundation.org/AMRF/amrf-investigators/
https://www.adelsonfoundation.org/AMRF/about-us/
https://www.yahoo.com/news/adelson-medical-re...00879.html
Speculation :
Perhaps The Adelson Medical Research Foundation is the "outside foundation" that's been quietly helping CYDY? Seems highly plausible to me, that at the very least, they're covering our Alzheimer's trial and stroke recovery research. Perhaps the Gates Foundation or a big pharma (in addition to NIH) is helping out with other potential Leronlimab indications (and the development of long-acting Leron), while Adelson shares in the heavy lifting.
What's clear is some entity (or entities... or a potential big pharma partner) has been helping us out in more ways than one. I'm guessing Adelson is a key charitable partner. Hopefully everyone's roles and contributions to CYDY / Leronlimab's development will be revealed soon.
If you do any Googling, keep in mind that Adelson has two separate and distinct charitable foundations; the one I'm referring to is the aforementioned *medical research* entity (not their "Family Foundation" which is for other purposes).
Worth watching (the CCR5 interview with Dr. Carmichael):
https://www.youtube.com/watch?v=xQb-z1k8fF8
________________________________________
As has been previously posted, Dr. Carmichael is also featured in a recent NYTimes article where he again discusses the importance of CCR5:
https://archive.is/20250908002038/https://www...-pill.html
Excerpted from CYDY's recent shareholder letter :
A new collaborator, Dr. Tom Carmichael, Professor and Chair of Neurology at the University of California, Los Angeles, has published important preclinical observations demonstrating how a small molecule CCR5 inhibitor can expedite recovery following a cerebrovascular accident (“CVA” or “stroke”). CytoDyn is working with Dr. Carmichael and Dr. Kate Schunke at the University of Hawaii to conduct a preclinical study of stroke in transgenic mice that express human CCR5 . We are excited by this initiative, given our view that there is an unmet need for innovative and effective treatment paths for patients in this category, and our belief that the market for therapies to treat stroke and/or traumatic brain injury could grow significantly over the next several decades. Dr. Carmichael will also be advising on the pilot study of Alzheimer's disease to be initiated at Cornell Medical Center in New York.
_______________________________________
I remain... #BULLISH
Some context:
"Can Blocking CCR5 Improve Brain Injury and Dementia Recovery?"
For those who haven't seen it, down below is a YouTube link to a very interesting CCR5-related interview with UCLA's Dr. Carmichael, who now collaborates with CYDY...
But first, it's worth noting that the "CCR5 inhibitor" used in Dr. Carmichael's prior studies is the generic drug Maraviroc, which has black box safety warnings (aka the highest level of warning the FDA can issue for a medication's dangerous side effects) for life-threatening liver toxicity. Maraviroc appears to be inferior to CYDY's Leronlimab in both safety and efficacy (Leronlimab has an impeccable safety profile with zero reports of serious adverse events). Importantly, Leronlimab also appears to do a superior job of crossing the blood-brain barrier.
It's worth reiterating that Dr. Carmichael is now collaborating with CytoDyn regarding Leronlimab.
Here's a very interesting tidbit that I found on him...
Dr. Carmichael also works closely with the "Adelson Medical Research Foundation".
Per Google, the net worth of the Adelson family is estimated to be around $40.4 billion.
Here's some additional info on the foundation and Dr. Carmichael's affiliation with it:
https://www.adelsonfoundation.org/AMRF/amrf-investigators/
https://www.adelsonfoundation.org/AMRF/about-us/
https://www.yahoo.com/news/adelson-medical-re...00879.html
Speculation :
Perhaps The Adelson Medical Research Foundation is the "outside foundation" that's been quietly helping CYDY? Seems highly plausible to me, that at the very least, they're covering our Alzheimer's trial and stroke recovery research. Perhaps the Gates Foundation or a big pharma (in addition to NIH) is helping out with other potential Leronlimab indications (and the development of long-acting Leron), while Adelson shares in the heavy lifting.
What's clear is some entity (or entities... or a potential big pharma partner) has been helping us out in more ways than one. I'm guessing Adelson is a key charitable partner. Hopefully everyone's roles and contributions to CYDY / Leronlimab's development will be revealed soon.
If you do any Googling, keep in mind that Adelson has two separate and distinct charitable foundations; the one I'm referring to is the aforementioned *medical research* entity (not their "Family Foundation" which is for other purposes).
Worth watching (the CCR5 interview with Dr. Carmichael):
https://www.youtube.com/watch?v=xQb-z1k8fF8
________________________________________
As has been previously posted, Dr. Carmichael is also featured in a recent NYTimes article where he again discusses the importance of CCR5:
https://archive.is/20250908002038/https://www...-pill.html
Excerpted from CYDY's recent shareholder letter :
A new collaborator, Dr. Tom Carmichael, Professor and Chair of Neurology at the University of California, Los Angeles, has published important preclinical observations demonstrating how a small molecule CCR5 inhibitor can expedite recovery following a cerebrovascular accident (“CVA” or “stroke”). CytoDyn is working with Dr. Carmichael and Dr. Kate Schunke at the University of Hawaii to conduct a preclinical study of stroke in transgenic mice that express human CCR5 . We are excited by this initiative, given our view that there is an unmet need for innovative and effective treatment paths for patients in this category, and our belief that the market for therapies to treat stroke and/or traumatic brain injury could grow significantly over the next several decades. Dr. Carmichael will also be advising on the pilot study of Alzheimer's disease to be initiated at Cornell Medical Center in New York.
_______________________________________
I remain... #BULLISH
35
